6.94
+0.01(+0.14%)
Currency In USD
| Previous Close | 6.93 |
| Open | 6.99 |
| Day High | 7.16 |
| Day Low | 6.88 |
| 52-Week High | 15.1 |
| 52-Week Low | 4.02 |
| Volume | 622,777 |
| Average Volume | 1.29M |
| Market Cap | 376.69M |
| PE | -2.69 |
| EPS | -2.58 |
| Moving Average 50 Days | 6.51 |
| Moving Average 200 Days | 7.69 |
| Change | 0.01 |
If you invested $1000 in Emergent BioSolutions Inc. (EBS) 10 years ago, it would be worth $203.58 as of July 22, 2025 at a share price of $6.94. Whereas If you bought $1000 worth of Emergent BioSolutions Inc. (EBS) shares 5 years ago, it would be worth $73.85 as of July 22, 2025 at a share price of $6.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participa
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
GlobeNewswire Inc.
Jul 08, 2025 8:45 PM GMT
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration fo
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
GlobeNewswire Inc.
Jul 02, 2025 8:05 PM GMT
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisisGAITHERSBURG, Md., July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions I